Inovio Pharmaceuticals Inc (INO) showcases significant progress in its BLA submission for INO-3107, while navigating ...

INOVIO Pharmaceuticals Inc. (NASDAQ:INO) shares fell 10% in early trading after the biotech company announced the pricing of a $25 million underwritten public offering at $1.90 per share, a discount ...

Investing.com -- INOVIO Pharmaceuticals Inc. (NASDAQ:INO) shares fell 10% after the biotechnology company announced the pricing of an underwritten public offering at $1.90 per share, representing a ...

The stock's rise snapped a four-day losing streak.

US biotech Inovio (Nasdaq: INO) said it plans to offer and sell shares of its common stock in an underwritten public offering ...

Pharmaceuticals announced that it intends to offer and sell shares of its common stock in an underwritten public offering. All of the ...

Chief Medical Officer Michael Sumner reported the BLA rolling submission was completed on October 30 and that the submission “clearly articulates the clinical efficacy of 3107 and demonstrates a ...

Good afternoon, ladies and gentlemen, and welcome to the Inovio Third Quarter 2025 Financial Results Conference Call. [Operator Instructions] This call is being recorded on Monday, November 10, 2025.

Shares of Inovio Pharmaceuticals Inc. INO shed 5.76% to $2.29 Wednesday, on what proved to be an all-around positive trading ...

PLYMOUTH MEETING, Pa. (AP) — PLYMOUTH MEETING, Pa. (AP) — Inovio Pharmaceuticals Inc. (INO) on Monday reported a loss of $45.5 million in its third quarter. On a per-share basis, the Plymouth Meeting, ...

INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and ...

INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and ...